Cardiol Therapeutics (NASDAQ:CRDL) Upgraded to “Strong-Buy” at Brookline Cap M

Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by stock analysts at Brookline Cap M to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports. Brookline Cap M also issued estimates for Cardiol Therapeutics’ Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.30) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.29) EPS.

CRDL has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiol Therapeutics in a report on Wednesday, October 8th. Brookline Capital Acquisition upgraded shares of Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a research note on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $9.00.

Cardiol Therapeutics Price Performance

CRDL stock traded up $0.03 during trading on Tuesday, hitting $0.99. The stock had a trading volume of 174,245 shares, compared to its average volume of 346,613. Cardiol Therapeutics has a twelve month low of $0.77 and a twelve month high of $1.59. The company’s 50-day moving average price is $1.00 and its two-hundred day moving average price is $1.09. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.89 and a quick ratio of 3.89. The stock has a market capitalization of $111.10 million, a P/E ratio of -3.32 and a beta of 1.04.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). As a group, research analysts predict that Cardiol Therapeutics will post -0.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Cardiol Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE raised its stake in Cardiol Therapeutics by 136.2% during the second quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after purchasing an additional 15,255 shares during the period. Thompson Davis & CO. Inc. acquired a new stake in shares of Cardiol Therapeutics during the 2nd quarter worth approximately $39,000. Boyer Financial Services Inc. purchased a new stake in shares of Cardiol Therapeutics during the 4th quarter valued at approximately $33,000. Tejara Capital Ltd lifted its holdings in Cardiol Therapeutics by 2.2% in the second quarter. Tejara Capital Ltd now owns 3,265,819 shares of the company’s stock valued at $4,442,000 after acquiring an additional 70,829 shares during the last quarter. Finally, Susquehanna International Group LLP increased its stake in Cardiol Therapeutics by 366.5% during the third quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after acquiring an additional 73,375 shares during the last quarter. 12.49% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Cardiol Therapeutics

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded Cardiol to a “Strong‑Buy” and reiterated bullish coverage, which likely lifted sentiment and buying interest. Zacks upgrade note
• Positive Sentiment: Brookline’s FY2026 EPS estimate is ($0.29), modestly better than the consensus ($0.33) — the smaller projected loss can be read as incremental fundamental improvement. Brookline estimates
• Neutral Sentiment: Brookline issued a set of quarterly EPS forecasts (Q4’25–Q4’26) centered around ($0.07)–($0.08) per quarter, which largely tracks existing expectations and signals steady — not dramatic — near‑term change. Brookline estimates
• Negative Sentiment: Despite the upgrade, Cardiol remains unprofitable with negative EPS, a small market cap and limited trading volume — risks that can cap upside until clinical or commercial milestones reduce execution and funding uncertainty. Company profile & metrics

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.